Eupraxia Pharmaceuticals Inc.
corporate_fare Company Profile
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for EPRX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-30, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 8/10, with 10 rated 8 or above. Recent SEC coverage for EPRX spans 6-K, SCHEDULE 13D/A, 40-F.
Recent high-impact activity:
- Eupraxia Reports 52-Week Durability Data from Highest Dose Cohort of EP-104GI in RESOLVE Trial
- Eupraxia Reports Durable Symptom Relief in EoE Trial, Including First Odynophagia Data
- Eupraxia Reports Q2 2026 Results: $133.6M Cash, Runway into 2H 2028, Phase 2b EoE Data Expected Q4
- Eupraxia Reshapes Executive Team Ahead of Pivotal EoE Data Readout
- Eupraxia Adds Three Pharma Veterans to Board, Bolstering Commercialization Expertise
Financial Snapshot
Short Interest & Short Volume
11.25 days to coverFINRA reported short interest of 7,582,355 shares in EPRX as of the September 15, 2026 settlement, a 6.6% increase from the prior period — about 11.3 days to cover at its recent average daily volume. On October 2, 2026, 62.2% of EPRX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for EPRX, detected from its recent SEC filings · based on capital-structure filings through 2026-08-06.
US$300M Universal Shelf Filed · No Immediate Dilution
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
EPRX files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.